celso de oliveira Rezende Júnior

Prof. Dr. celso de oliveira Rezende Júnior

Universidade Federal de Uberlândia, Uberlândia, MG, Brazil
orcid

Research Focus & Metrics

Academic Career Length

19Years (2008-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
11 March 2015 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Closed access
PDF file
Fang BaiFang Bai
Fang Bai
FMFaruck Morcos
Faruck Morcos
YSYang-Sung Sohn
Yang-Sung Sohn
MDMerav Darash-Yahana
Merav Darash-Yahana
celso de oliveira Rezende Júniorcelso de oliveira Rezende Júnior
celso de oliveira Rezende Júnior
RNRachel Nechushtai
Rachel Nechushtai
Significance: Cancer is a leading cause of mortality worldwide, with the identification of novel drug targets and chemotherapeutic agents being a high priority in the fight against it. The NEET proteins mitoNEET (mNT) and nutrient-deprivation autophagy factor-1 (NAF-1) were recently shown to be required for cancer cell proliferation. Utilizing a combination of experimental and computational techniques, we identified a derivative of the mitocan cluvenone that binds to NEET proteins at the vicinity of their 2Fe-2S clusters and facilitates their destabilization. The new drug displays a high specificity in the selective killing of human epithelial breast cancer cells, without any apparent effects on normal breast cells. Our results identify the 2Fe-2S clusters of NEET proteins as a novel target in the chemotherapeutic treatment of breast cancer.

18 June 2015 in Oncotarget
Verified
Journal Article
Open access
PDF file
ETEmmanuel Theodorakis
Emmanuel Theodorakis
celso de oliveira Rezende Júniorcelso de oliveira Rezende Júnior
celso de oliveira Rezende Júnior
OCOraphin Chantarasriwong
Oraphin Chantarasriwong
ACAdriana D. Corben
Adriana D. Corben
ETEmmanuel A. Theodorakis
Emmanuel A. Theodorakis
MAMary L. Alpaugh
Mary L. Alpaugh
Spontaneously-forming spheroids as an in vitro cancer cell model for anticancer drug screening Spontaneously-forming spheroids as an in vitro cancer cell model for anticancer drug screening

22 December 2015 in Virology Journal
Verified
Journal Article
Open access
PDF file
PZPaula Rodrigues Zanello
Paula Rodrigues Zanello
AKAndrea Cristine Koishi
Andrea Cristine Koishi
celso de oliveira Rezende Júniorcelso de oliveira Rezende Júnior
celso de oliveira Rezende Júnior
LOLarissa Albuquerque Oliveira
Larissa Albuquerque Oliveira
APAdriane Antonia Pereira
Adriane Antonia Pereira
JBJuliano Bordignon
Juliano Bordignon
Dengue is the most prevalent arboviral disease in tropical and sub-tropical areas of the world. The incidence of infection is estimated to be 390 million cases and 25,000 deaths per year. Despite these numbers, neither a specific treatment nor a preventive vaccine is available to protect people living in areas of high risk. With the aim of seeking a treatment that can mitigate dengue infection, we demonstrated that the quinic acid derivatives known as compound 2 and compound 10 were effective against all four dengue virus serotypes and safe for use in a human hepatoma cell line (Huh7.5). Both compounds were non-virucidal to dengue virus particles and did not interfere with early steps of the dengue virus life cycle, including binding and internalization. Experiments using a replicon system demonstrated that compounds 2 and 10 impaired dengue virus replication in Huh7.5 cells. Additionally, the anti-dengue virus effects of the quinic acid derivatives were preserved in human peripheral blood mononuclear cells. Taken together, these data suggest that quinic acid derivatives represent a novel chemical class of active compounds that could be used to combat dengue virus infection.

25 November 2019 in Journal of Chemical Information and Modeling
Verified
Journal Article
Closed access
MSMariana L. de Souza
Mariana L. de Souza
celso de oliveira Rezende Júniorcelso de oliveira Rezende Júnior
celso de oliveira Rezende Júnior
RFRafaela Salgado Ferreira
Rafaela Salgado Ferreira
RCRocio Marisol Espinoza Chávez
Rocio Marisol Espinoza Chávez
LFLeonardo Luiz Gomes Ferreira
Leonardo Luiz Gomes Ferreira
AAAdriano Andricopulo
Adriano Andricopulo

25 November 2019 in Frontiers in Chemistry
Verified
Journal Article
Open access
PDF file
RFRafael A. A. Ferreira
Rafael A. A. Ferreira
IPIvani Pauli
Ivani Pauli
TSThiago S. Sampaio
Thiago S. Sampaio
MSMariana L. de Souza
Mariana L. de Souza
LFLeonardo L. G. Ferreira
Leonardo L. G. Ferreira
AAAdriano Andricopulo
Adriano Andricopulo
Chagas disease causes ~10,000 deaths each year, mainly in Latin America, where it is endemic. The currently available chemotherapeutic agents are ineffective in the chronic stage of the disease, and the lack of pharmaceutical innovation for Chagas disease highlights the urgent need for the development of new drugs. The enzyme cruzain, the main cysteine protease of Trypanosoma cruzi, has been explored as a validated molecular target for drug discovery. Herein, the design, molecular modeling studies, synthesis, and biological evaluation of cyclic imides as cruzain inhibitors are described. Starting with a micromolar-range cruzain inhibitor (3a, IC50 = 2.2 μM), this molecular optimization strategy resulted in the nanomolar-range inhibitor 10j (IC50 = 0.6 μM), which is highly active against T. cruzi intracellular amastigotes (IC50 = 1.0 μM). Moreover, most compounds were selective toward T. cruzi over human fibroblasts, which were used as host cells, and are less toxic to hepatic cells than the marketed drug benznidazole. This study enabled the discovery of novel chemical diversity and established robust structure-activity relationships to guide the design of optimized cruzain inhibitors as new trypanocidal agents.

1 February 2012 in International Immunopharmacology
Verified
Journal Article
Closed access
SCSandra Castro
Sandra Castro
celso de oliveira Rezende Júniorcelso de oliveira Rezende Júnior
celso de oliveira Rezende Júnior
Caio Cesar Souza AlvesCaio Cesar Souza Alves
Caio Cesar Souza Alves
ADAlyria T. Dias
Alyria T. Dias
LALívia L. Alves
Lívia L. Alves
AFAna Paula Ferreira
Ana Paula Ferreira